Novo Nordisk Executive Martin Holst Lange Sells Shares to Cover Tax Obligations

Executive Share Sale at Novo Nordisk

Martin Holst Lange, the Executive Vice President for Research & Development and Chief Scientific Officer (CSO) at Danish pharmaceutical giant Novo Nordisk A/S, executed a sale of company shares on February 9, 2026. The transaction involved 22,000 Novo Nordisk B shares, which were sold on Nasdaq Copenhagen for a total value of DKK 7,035,600 (approximately 7.04 million Danish Kroner).

Purpose of the Transaction

The primary reason for the share sale was to fulfill tax obligations. These taxes are associated with shares that Mr. Lange received as part of Novo Nordisk's long-term incentive program. Such sales are a common practice among executives to manage the tax implications of equity-based compensation. The shares were sold at a price of DKK 319.80 per share.

Transparency and Compliance

Novo Nordisk disclosed the transaction on February 10, 2026, in accordance with European market abuse regulations, specifically Article 19 of Regulation No. 596/2014. This disclosure underscores the company's commitment to transparency regarding insider transactions. The company stated that this routine disposal of incentive-related shares does not signal a change in corporate strategy.

Martin Holst Lange's Role

As Executive Vice President for R&D and Chief Scientific Officer, Martin Holst Lange plays a crucial role in Novo Nordisk's strategic direction and innovation efforts. He joined Novo Nordisk in 2002 and has held various positions within the medical and clinical development functions. Novo Nordisk, headquartered in Denmark, is a leading global healthcare company focused on defeating serious chronic diseases.